The effect of growth hormone treatment on height in children with idiopathic short stature.

Abstract

Idiopathic short stature (ISS) is short stature of unknown cause. In 2003, the Food and Drug Administration (FDA) approved the use of growth hormone (GH) for ISS. Several studies have evaluated the effect of GH in children with ISS, in whom improved growth velocities and height standard deviation scores (SDS) have been reported. However, clinical variables influence the height improvement. This study aimed to evaluate the effects of GH treatment on ISS and to analyze clinical factors associated with growth velocity. This study was conducted retrospectively. Subjects diagnosed with ISS at Ajou University Hospital were divided into two groups, an ISS with GH-treatment group (n=34) and an ISS control group (n=36). All children were prepubertal, and aged <10 years. We reviewed their auxological data, laboratory findings, and bone age. Growth velocity of the GH-treatment group exceeded that of controls by 3.37 cm/year (95% CI, 2.78-3.95). At baseline, the mean SDS for height in the treatment and control groups were equivalent (-2.25 ± 0.29 and -2.22 ± 0.31, respectively). However, after 1 year, the height of the GH-treated group exceeded that of the control group by 0.73 SDS (95% CI, 0.57-0.88). A negative correlation was found between age and growth velocity in the GH-treatment group. GH treatment increased short-term growth velocity and height SDS of Korean children with ISS. Age was identified as the single most important factor correlated with growth velocity in GH treatment.